IMPORE OF GIVINO 2 2 MAR 2006

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93855

Shinya KUSUDA, et al.

Appln. No.: Based on PCT/JP04/014137

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: March 22, 2006

Examiner: Unknown

For:

PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME,

AND USE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/572937

IAFY REC'EPTIPED 22 MAR 2005

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP04/014137

Attorney Docket No.: Q93855

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP04/014137 dated November 9, 2004), together with an English-language

version (if not already included) of at least that portion of the Communication indicating the

degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Mark Boland

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373 CUSTOMER NUMBER

Date: March 22, 2006

Mark Boland

Registration No. 32,197

2

MODIFIED PTO/SR/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

```?9 Rec'd&	1 MAR 2006
Application Number	Based on PCT/JP04/014137
Confirmation Number	Unknown
Filing Date	March 22, 2006
First Named Inventor	Shinya KUSUDA
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	O93855

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1		Document N	umber		
			Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US	· <u>-</u>			
		US			, <u> </u>	
		US				
		US				
		US				
		US				
	-	US				
		US			-	
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		WO	99/46232	A1	09-16-1999	Ono Pharmaceutial Co., Ltd.	
		WO	03/72102	A1	09-04-2003	Eli Lilly and Co.	
		JP	2002-265457	A	09-18-2002	Takeda Chemical Industries, Ltd.	
		WO	03/721000	A1	09-04-2003	Eli Lilly and Co.	
			, , , , , , , , , , , , , , , , , , , ,				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶	
		International Search Report for PCT/JP04/014137 dated November 9, 2004		
			<del> </del>	

		Data Canaldanad	
Examiner Signature		Date Considered	
<u> </u>			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.